CN111132983A - 一种异喹啉磺酰衍生物的晶型及其制备方法 - Google Patents

一种异喹啉磺酰衍生物的晶型及其制备方法 Download PDF

Info

Publication number
CN111132983A
CN111132983A CN201880062448.2A CN201880062448A CN111132983A CN 111132983 A CN111132983 A CN 111132983A CN 201880062448 A CN201880062448 A CN 201880062448A CN 111132983 A CN111132983 A CN 111132983A
Authority
CN
China
Prior art keywords
degrees
compound
formula
crystal form
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880062448.2A
Other languages
English (en)
Other versions
CN111132983B (zh
Inventor
姚元山
陈兆国
陈志娟
吴凌云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Resources Pharmaceutical Holdings Co Ltd
Original Assignee
China Resources Pharmaceutical Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Resources Pharmaceutical Holdings Co Ltd filed Critical China Resources Pharmaceutical Holdings Co Ltd
Publication of CN111132983A publication Critical patent/CN111132983A/zh
Application granted granted Critical
Publication of CN111132983B publication Critical patent/CN111132983B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

本发明公开了一种Rho蛋白激酶抑制剂的盐型、晶型、制备方法及其医药用途。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201880062448.2A 2017-09-25 2018-09-20 一种异喹啉磺酰衍生物的晶型及其制备方法 Active CN111132983B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710874795 2017-09-25
CN2017108747952 2017-09-25
PCT/CN2018/106745 WO2019057121A1 (zh) 2017-09-25 2018-09-20 一种异喹啉磺酰衍生物的晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN111132983A true CN111132983A (zh) 2020-05-08
CN111132983B CN111132983B (zh) 2022-05-17

Family

ID=65810677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880062448.2A Active CN111132983B (zh) 2017-09-25 2018-09-20 一种异喹啉磺酰衍生物的晶型及其制备方法

Country Status (2)

Country Link
CN (1) CN111132983B (zh)
WO (1) WO2019057121A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114746431A (zh) * 2019-10-18 2022-07-12 贵州伊诺其尼科技有限公司 一种lrrk2抑制剂的晶型及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227581A (ja) * 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
CN1210521A (zh) * 1996-02-02 1999-03-10 日本新药株式会社 异喹啉衍生物及医药
WO2004106325A1 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
US20050272751A1 (en) * 2004-02-24 2005-12-08 Bioaxone Therapeutique Inc. 4-Substituted piperidine derivatives
CN101622243A (zh) * 2007-02-28 2010-01-06 旭化成制药株式会社 磺酰胺衍生物
CN105085525A (zh) * 2014-04-28 2015-11-25 南京明德新药研发股份有限公司 作为rho激酶抑制剂的异喹啉磺酰衍生物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227581A (ja) * 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
CN1210521A (zh) * 1996-02-02 1999-03-10 日本新药株式会社 异喹啉衍生物及医药
WO2004106325A1 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
US20050272751A1 (en) * 2004-02-24 2005-12-08 Bioaxone Therapeutique Inc. 4-Substituted piperidine derivatives
CN101622243A (zh) * 2007-02-28 2010-01-06 旭化成制药株式会社 磺酰胺衍生物
CN105085525A (zh) * 2014-04-28 2015-11-25 南京明德新药研发股份有限公司 作为rho激酶抑制剂的异喹啉磺酰衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吕扬 等: "《晶型药物》", 31 October 2009, 人民卫生出版社 *

Also Published As

Publication number Publication date
WO2019057121A1 (zh) 2019-03-28
CN111132983B (zh) 2022-05-17

Similar Documents

Publication Publication Date Title
JP5702396B2 (ja) ベンゾジアゼピンブロモドメイン阻害剤
ES2648288T3 (es) Formas cristalinas de sulfato de 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-(4-piridin-3-il-pirimidin-2-il-amino)-benzamida y su forma amorfa
US11629153B2 (en) Forms and compositions of a MK2 inhibitor
AU2014239995A1 (en) Salt of omecamtiv mecarbil and process for preparing salt
WO2014093583A2 (en) Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof
AU2019303777B2 (en) Salt of LSD1 inhibitor and a polymorph thereof
CN111132983B (zh) 一种异喹啉磺酰衍生物的晶型及其制备方法
KR20230061444A (ko) Rho-연관 단백질 인산화효소 억제제의 염, 염의 고체 형태, 이의 제조 방법 및 이의 용도
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
US20220242873A1 (en) Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt
KR101446789B1 (ko) 1-((2Ｓ)-2-아미노-4-(2,4-비스(트리플루오로메틸)-5,8-디히드로피리도(3,4-ｄ)피리미딘-7(6Ｈ)-일)-4-옥소부틸)-5,5-디플루오로피페리딘-2-온 타트레이트염의 수화물
WO2022199591A1 (zh) 一种氟取代的吡啶并吡唑类化合物的晶型及其制备方法
CN109721531B (zh) 一种新型的脂质体激酶抑制剂
CN111448185A (zh) 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法
KR102183356B1 (ko) Fgfr 억제제를 제조하기 위한 방법
CN109563097A (zh) 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法
WO2013181251A9 (en) Crizotinib hydrochloride salt in crystalline
JP7076565B2 (ja) Ｆｇｆｒ４阻害剤として用いられる化合物の塩形態、結晶形及びその製造方法
JPH0357895B2 (zh)
JP2022523035A (ja) １，２，３－トリアゾロ［１，５－ａ］ピラジン誘導体の結晶形および結晶形の調製方法
WO2023138681A1 (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
CN108864063A (zh) 一种治疗癌症的药物溶剂合物及其制备方法
BR112020006051A2 (pt) formas cristalinas de lenalidomida
CN111757871B (zh) 一种Caspase抑制剂的结晶
RU2787767C2 (ru) Кристалл производного бензоксазола

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant